T-regulatory lymphocytes in gastrointestinal cancer

January 31, 2011

A research team from Poland and United Kingdom assessed the absolute number of T-regulatory cells in the peripheral blood of gastric and colorectal cancer patients. The study showed the absolute number of Tregs in the peripheral blood of gastric cancer patients was significantly decreased in comparison to that in the healthy controls.

T-regulatory lymphocytes (Tregs) are a subset of that are involved in the mechanism of immunotolerance to self- and allo-antigens. Activity of these cells is one of the mechanisms of immune evasion of tumors, which inhibits the antitumor activity of effector . Tregs are among the tumor-infiltrating lymphocytes and circulate in the peripheral blood. In various cancer types, increased prevalence of Tregs has been observed, and in some studies, this has been reported as a prognostic factor.

A research article published on January 21, 2011 in the addresses this question. The authors studied the peripheral blood Tregs as a potential disease marker, which was relatively easy to measure during pretreatment and follow-up periods.

The results indicated that the absolute number of Tregs in peripheral blood of but not colorectal cancer patients was significantly decreased in comparison with that in healthy controls. The findings suggest that the population of Tregs in peripheral blood does not simply mimic stromal Tregs. Further studies on larger groups of patients are necessary to evaluate the Treg population in cancer patients.

More information: Szczepanik AM, Siedlar M, Sierzega M, Goroszeniuk D, Bukowska-Strakova K, Czupryna A, Kulig J. T-regulatory lymphocytes in peripheral blood of gastric and colorectal cancer patients. World J Gastroenterol 2011; 17(3): 343-348. www.wjgnet.com/1007-9327/full/v17/i3/343.htm

Related Stories

Recommended for you

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

Scientists restore tumor-fighting structure to mutated breast cancer proteins

September 20, 2017
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides ...

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

Researchers identify new target, develop new drug for cancer therapies

September 20, 2017
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

Brain powered: Increased physical activity among breast cancer survivors boosts cognition

September 19, 2017
It is estimated that up to 75 percent of breast cancer survivors experience problems with cognitive difficulties following treatments, perhaps lasting years. Currently, few science-based options are available to help. In ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.